“ADVM has been the topic of several other reports.

Adverum Biotechnologies said Tuesday the effect of its gene therapy on an eye disease lasted more than a year — prodding ADVM stock to rocket.. X. A Look At Adverum Biotechnologies (NASDAQ:ADVM) With the previous 100-day trading volume average of 1.42 million shares, Adverum Biotechnologies (ADVM) recorded a trading volume of 1.19 million shares, as the stock started the trading session at the value of $12.91, in the end touching the price of $14.06 after jumping by 8.91%. INVESTOR & MEDIA CONTACTS: Investors: Myesha Lacy Adverum Biotechnologies, Inc. 1-650-304-3892 Media: Cherilyn Cecchini, M.D. Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). IBD Subscribers also enjoy ongoing investor training and support. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Stock Investing Tools designed to help you analyze and strategize stocks for successful investing.Find winning stocks before they break out with IBD's exclusive stock lists.The Big Picture article signals when to be in or out of the market to maximize gains.© 2019 Investor's Business Daily, Inc. All rights reserved.Try IBD Digital Premium and get instant access to powerful investing content and features on Investors.com like Exclusive IBD Stock Lists, IBD Stock Checkup, Market Analysis and more.

Subscription includes access to all devices.

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Adverum Biotechnologies, Inc. ("Adverum " or the "Company" (NASDAQ: ADVM) on behalf of investors. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) traded at $18.42 at last check on Tuesday, Jul 14, making an upward move of 0.77% on its previous day’s price. As a group, analysts predict that Adverum Biotechnologies will post -1.23 EPS for the current fiscal year. Cantor Fitzgerald upped their price objective on shares of Adverum Biotechnologies from $21.00 to $36.00 and gave the company an overweight rating in a research note on Wednesday, July 8th. Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Adverum Biotechnologies by 20.7% in the first quarter. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Find the latest Adverum Biotechnologies, Inc. (ADVM) stock quote, history, news and other vital information to help you with your stock trading and investing.